H.R.1548 - Pathway for Biosimilars Act

To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. view all titles (2)

All Bill Titles

  • Short: Pathway for Biosimilars Act as introduced.
  • Official: To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. as introduced.

This Bill currently has no wiki content. If you would like to create a wiki entry for this bill, please Login, and then select the wiki tab to create it.

Bill’s Views

  • Today: 2
  • Past Seven Days: 3
  • All-Time: 18,147
 
Introduced
 
House
Passes
 
Senate
Passes
 
President
Signs
 

 
03/17/09
 
 
 
 
 
 
 

Sponsor

Representative

Anna Eshoo

D-CA

View Co-Sponsors (149)

Official Summary

Pathway for Biosimilars Act - Amends the Public Health Service Act to allow a person to submit an application for licensure of a biological product based on its similarity to a licensed biological product (the reference product).Requires the Secretary of Health and Human Services to approve

Official Summary

Pathway for Biosimilars Act - Amends the Public Health Service Act to allow a person to submit an application for licensure of a biological product based on its similarity to a licensed biological product (the reference product).Requires the Secretary of Health and Human Services to approve the application if:
(1) the biological product is biosimilar to the reference product with respect to each condition of use for which the reference product is approved; and
(2) the applicant consents to the inspection of the facility that is the subject of the application. Sets forth requirements for a determination by the Secretary that a biological product is interchangeable with a reference product.Prohibits a biological product from being evaluated against more than one reference product. Prohibits licensure under this Act of a biological product containing specified agents or toxins or a schedule I or II controlled substance unless the Secretary determines there would be no increased risk to the security or health of the public from licensing such a biological product. Prohibits the Secretary from making approval of an application under this Act effective until 12 yeas after the date on which the reference product was first licensed.Provides for confidentiality of information received pursuant to this Act.Sets forth provisions governing patent infringement actions related to this Act.Deems as patent infringement the submission of a statement under this Act by the applicant setting forth reasons why the making, use, or sale of the biosimilar product would not infringe the patent, or why the patent is invalid or unenforceable, if the purpose of such submission is to obtain approval to engage in the commercial manufacture, use, or sale before the expiration of such patent.

...Read the Rest

Organizations Supporting H.R.1548

  • Biotechnology Industry Organization
  • California Healthcare Institute

Organizations Opposing H.R.1548

  • Generic Pharmaceutical Association




Vote on This Bill

100% Users Support Bill

3 in favor / 0 opposed
 

Send Your Rep a Letter

about this bill Support Oppose Tracking
Track with MyOC